BLOG

The Biotech Buying Bonanza: Why The FTC’s Amgen Battle Won’t Chill The Spree

Reata is a biotech stock with a perfect Relative Strength Rating of 99, putting its 12-month price performance in the top 1% of all stocks, according to IBD Digital.